Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From People
This week's roundup sees Sanofi appoint Biogen's former SVP of corporate affairs to executive vice president, external affairs. Meanwhile, Galena Biopharma, Abpro, Genmab and Purdue Pharma have all named new executives.
This week's roundup includes the appointments of chief medical officers by both Avillion and X4 Pharmaceuticals and various other senior appointments at Summit Therapeutics, Sosei, Ipsen and Kymab.
Women fill many roles in biopharma companies, but relatively few are in leadership positions. Executives who spoke with Scrip in a roundtable discussion during the J.P. Morgan Healthcare Conference earlier this month noted the disconnect, but saw some hope for improved gender diversity in the future.
Moving from China president to a CEO, from regional Asia head to a global pharmaceutical president, several recent senior executive appointments have people wondering if China is increasingly becoming the new launch pad for high flyers eyeing a global pharma leadership role.
Scrip decided to shake things up a bit for its third annual biopharmaceutical executive roundtable held during the J.P. Morgan Healthcare Conference by putting together an all-female panel to talk about the financing and dealmaking landscape as well as the state of women in the industry.
This week's roundup includes board appointments by Pharmalink, Oxular, Decibel Therapeutics and executive appointments by various companies including e-Therapeutics, where Amgen's current executive director of corporate development has been appointed CEO, Cleave Biosciences and IXICO.
"Succession processes are challenging for everyone involved and, unfortunately, it is rare that all of those involved stay with the company," stated GSK's out-going CEO Andrew Witty, as Abbas Hussain decides to leave the company having lost out on the top job, which went to Emma Walmsley. His successor will be AstraZeneca's Luke Miels.
From general managers of multinationals to new CEOs of domestic innovative startups, a string of recently minted executives will help shape the future of the pharma industry in China.
Sobi's outgoing US-based CEO says his extended handover will “maintain continuity” as Sweden's rare disease specialist searches for a successor who will "stay closer to home" as it conducts key product launches.
2017 begins with three Novartis executives finding new roles and high-level appointments made by Shire, Bicycle Therapeutics, Gilead Science and Amplyx Pharmaceuticals.
Shaw is the former US President of rival Novartis and a rising figure in big pharma. She will take over the role previously held by Ricks, who became CEO Jan. 1. Conterno will assume President USA role.
The Scrip editorial team have put their heads together to make a list of the people that we believe have shaped the biopharma industry in 2016 – in terms of reputation, innovation or commercialization. In the way of Time magazine's 'Person of the Year', inclusion on the list is not necessarily an accolade…
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.